Neurologia最新文献

{"title":"Neuropsychological rehabilitation for post–COVID-19 syndrome: results of a clinical programme and six-month follow up","authors":"","doi":"10.1016/j.nrleng.2022.06.007","DOIUrl":"10.1016/j.nrleng.2022.06.007","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with post-COVID-19 syndrome may present cognitive and emotional symptomatology. This study aims to analyse the results of an outpatient neuropsychological intervention programme for post-COVID-19 syndrome.</p></div><div><h3>Method</h3><p>In June 2020 Institut Guttmann started an outpatient post-COVID-19 neurorehabilitation programme, including respiratory therapy, physiotherapy, and neuropsychological rehabilitation. Before and after the programme, the cognitive-emotional state of all participants is assessed. Six months after treatment, a follow-up assessment is administered (which includes a collection of information on various aspects of daily life).</p></div><div><h3>Results</h3><p>The sample analysed consisted of 123 patients (mean age: 51 years, SD: 12.41). Seventy-four per cent (n = 91) had cognitive impairment and underwent cognitive treatment (experimental group); the remaining 26% (n = 32) constituted the control group. After the intervention, the experimental group improved in working memory, verbal memory (learning, recall and recognition), verbal fluency and anxious-depressive symptomatology. The control group showed changes in immediate memory, verbal memory (learning and recognition) and depressive symptomatology, although the effect size in the latter two was smaller than in the experimental group. Six months after treatment, 44.9% of the patients were unable to perform their pre-COVID-19 work activity, and 81.2% reported difficulties in their activities of daily living.</p></div><div><h3>Conclusions</h3><p>Neuropsychological rehabilitation is an effective tool to treat the cognitive-emotional deficits present in post-COVID-19 syndrome. However, months after the end of treatment, not all patients recover their pre-COVID-19 functional level.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 7","pages":"Pages 592-603"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9548210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volume of hippocampal activation as a determining factor for the lateralisation of the epileptogenic zone in patients with drug-resistant mesial temporal lobe epilepsy","authors":"","doi":"10.1016/j.nrleng.2022.02.003","DOIUrl":"10.1016/j.nrleng.2022.02.003","url":null,"abstract":"<div><h3>Introduction</h3><p>Approximately 30% of patients with mesial temporal lobe epilepsy (MTLE) will develop drug resistance, which requires early surgical treatment. The success of the surgical procedure largely depends on the correct lateralisation of the epileptogenic zone, which can only be determined in 70% of patients with such conventional diagnostic tools as video electroencephalography and volumetric structural magnetic resonance imaging. We evaluated the performance of a memory functional magnetic resonance imaging (fMRI) paradigm in lateralising the epileptogenic zone in patients with drug-resistant MTLE.</p></div><div><h3>Methods</h3><p>We included 18 patients with MTLE attended at the Instituto Neurológico Colombiano in Medellin (Colombia) between 2018 and 2019. The volume of functional activation in both temporal lobes was determined with a memory fMRI paradigm. A concordance analysis was performed to compare the performance of fMRI against that of conventional tests.</p></div><div><h3>Results</h3><p>In patients with left MTLE, lower total activation was found in the hemisphere ipsilateral to the epileptogenic zone as compared to the contralateral hemisphere (121.15 ± 16.48 voxels vs 170.23 ± 17.8 voxels [<em>P</em> &lt; .001]), showing substantial concordance with conventional tests. Patients with right MTLE displayed lower hippocampal activation ipsilateral to the epileptogenic zone (18.5 ± 3.38 voxels vs 27.8 ± 3.77 voxels in the contralateral hippocampus [<em>P</em> = .048]), showing moderate concordance with conventional tests.</p></div><div><h3>Conclusions</h3><p>These findings suggest that lower functional activation as determined by a memory fMRI paradigm has a high level of concordance with conventional tests for lateralising the epileptogenic zone in patients with drug-resistant MTLE.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 7","pages":"Pages 584-591"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580822001754/pdfft?md5=d003c84ef8e34690847de920050a2682&pid=1-s2.0-S2173580822001754-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creutzfeldt–Jakob disease in a heterozygous GBA mutation carrier: Coincidence or consequence?","authors":"I.V. Carvalho ,&nbsp;D. Damas ,&nbsp;I. Baldeiras ,&nbsp;M.R. Almeida ,&nbsp;H. Gens ,&nbsp;G.C. Santo","doi":"10.1016/j.nrleng.2024.07.005","DOIUrl":"10.1016/j.nrleng.2024.07.005","url":null,"abstract":"","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 7","pages":"Pages 614-616"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000683/pdfft?md5=187a41b651794a732165a10e8f660b4a&pid=1-s2.0-S2173580824000683-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating microRNAs as potential biomarkers for the diagnosis of Parkinson's disease: A meta-analysis","authors":"W.T. Zhang ,&nbsp;Y.J. Wang ,&nbsp;Y.F. Yao ,&nbsp;G.X. Zhang ,&nbsp;Y.N. Zhang ,&nbsp;S.S. Gao","doi":"10.1016/j.nrleng.2024.07.004","DOIUrl":"10.1016/j.nrleng.2024.07.004","url":null,"abstract":"<div><h3>Background and objective</h3><p>Parkinson's disease (PD) is the one of the most common neurodegenerative diseases. Many investigators have confirmed the possibility of using circulating miRNAs to diagnose PD. However, the results were inconsistent. Therefore, the aim of this meta-analysis was to systematically evaluate the diagnostic accuracy of circulating miRNAs in the diagnosis of PD.</p></div><div><h3>Methods</h3><p>We carefully searched PubMed, Embase, Web of Science, Cochrane Library, Wanfang database and China National Knowledge Infrastructure for relevant studies (up to January 1, 2022) based on PRISMA statement. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), the diagnostic odds ratio (DOR), and area under the curve (AUC) were calculated to test the diagnostic accuracy. Furthermore, subgroup analyses were performed to identify the potential sources of heterogeneity, and the Deeks’ funnel plot asymmetry test was used to evaluate the potential publication bias.</p></div><div><h3>Results</h3><p>Forty-four eligible studies from 16 articles (3298 PD patients and 2529 healthy controls) were included in the current meta-analysis. The pooled sensitivity was 0.79 (95% CI: 0.76–0.81), specificity was 0.82 (95% CI: 0.78–0.84), PLR was 4.3 (95% CI: 3.6–5.0), NLR was 0.26 (95% CI: 0.23–0.30), DOR was 16 (95% CI: 13–21), and AUC was 0.87 (95% CI: 0.84–0.90). Subgroup analysis suggested that miRNA cluster showed a better diagnostic accuracy than miRNA simple. Moreover, there was no significant publication bias.</p></div><div><h3>Conclusions</h3><p>Circulating miRNAs have great potential as novel non-invasive biomarkers for PD diagnosis.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 7","pages":"Pages 573-583"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000671/pdfft?md5=b25a2085afa43ffd027bc10248093d00&pid=1-s2.0-S2173580824000671-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valproic acid could help in the fight against COVID-19: A case–control study","authors":"O. Moreno-Pérez ,&nbsp;E. Merino ,&nbsp;J. Manuel Ramos ,&nbsp;J. Carlos Rodríguez ,&nbsp;C. Diaz ,&nbsp;P. Mas ,&nbsp;S. Reus ,&nbsp;R. Sánchez-Martínez ,&nbsp;V. Boix ,&nbsp;P. Chico-Sánchez ,&nbsp;J. Sánchez-Payá ,&nbsp;J. Portilla ,&nbsp;On behalf COVID19-ALC research group","doi":"10.1016/j.nrleng.2023.12.009","DOIUrl":"10.1016/j.nrleng.2023.12.009","url":null,"abstract":"<div><h3>Objective</h3><p>There is early evidence about Valproic acid (VPA) antiviral effect. Our aim was to investigate the incidence and severity of SARS-CoV-2 infection in VPA users as compared with the general population.</p></div><div><h3>Material and methods</h3><p>A case-control study nested within a cohort, carried out between March 1 and December 17, 2020. Retrospectively, we identified confirmed SARS-CoV-2 infection patients exposed to VPA in our health department (defined as case). We ascertained VPA regimen (all the time (AT) (292 days) or at least 20% of the study period (notAT) (≥58 days) and if VPA levels were in therapeutic range (ATR) (50–100<!--> <!-->mcg/mL) in the last 24 months. We calculated the cumulative incidence of SARS-CoV-2 infection and hospital admission in the cases, comparing it with the general unexposed VPA population (controls).</p></div><div><h3>Results</h3><p>During the study period, 6183 PCR+ were detected among 281,035 inhabitants, of these, 746 were hospitalized. 691 patients were on VPA notAT and 628 (90.1%) AT. The indication for VPA use was epilepsy in 54.9%. The incidence of PCR+ was 1.736% (OR 0.785 (95%CI 0.443–1.390) and 1.910% (OR 0.865 (95%CI 0.488–1.533), on VPA notAT and VPA AT patients, respectively vs. 2.201% in people without VPA regimen. Those patients with VPA ATR had a lower risk of PCR + (OR 0.233 (95%CI 0.057–0.951) notAT; OR 0.218 (95%CI 0.053–0.890) AT). Hospital admission incidence was lower in patient on VPA (OR was 0.543 (95% CI 0.076–3.871).</p></div><div><h3>Conclusion</h3><p>Patients with VPA within the therapeutic range had a reduction of SARS-Cov-2 infection incidence greater than 75%. There is a downward trend in the risk of COVID-19 admission by SARS-CoV-2 in patients on VPA therapy. These findings warrant further investigation.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 7","pages":"Pages 549-554"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580823000779/pdfft?md5=6b9d346c962f2cb227f986f1ec687e0c&pid=1-s2.0-S2173580823000779-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombectomy with embed aspiration in acute ischaemic stroke","authors":"","doi":"10.1016/j.nrleng.2021.09.013","DOIUrl":"10.1016/j.nrleng.2021.09.013","url":null,"abstract":"<div><h3>Background</h3><p>In addition to stent retrievers, direct aspiration has become a reasonable thrombectomy strategy.</p></div><div><h3>Objectives</h3><p>We carried out the thrombectomy by guiding the aspiration catheter fully over the clot and performing immediate manual aspiration; we call this procedure “embed aspiration”.</p></div><div><h3>Methods</h3><p>In this prospective, non-randomised, single-centre study, we included all patients treated at a high volume-of-care stroke centre between 2017 and 2018 for the TRIANA (Thrombectomy in Andalusia using Aspiration) registry. Thrombectomy was carried out by embed aspiration. Patients were classified according to the success (eTICI 2b67-2c-3) or failure (eTICI 0-1-2a-2b50) of the procedure. Baseline clinical data and outcomes were compared, and multivariate analysis was performed.</p></div><div><h3>Results</h3><p>The embed aspiration technique was used in 370 patients. Treatment was successful in 90.3% of patients. Mean puncture-to-recanalisation time was 25 minutes. The overall rate of good outcomes (mRS 0–2) at 3 months was 64%.</p></div><div><h3>Conclusions</h3><p>This study supports real-life evidence that standardised embed aspiration may be an alternative to stent retrievers for thrombectomy.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 7","pages":"Pages 530-539"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580823000305/pdfft?md5=ad451f1d606be9bf1e0df6fba02f6e51&pid=1-s2.0-S2173580823000305-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9428822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the effect of botulinum toxin A on the physical and mental health of patients with hemifacial spasm","authors":"J.S. Wei ,&nbsp;X. Hu ,&nbsp;L. Xia ,&nbsp;J. Shang ,&nbsp;Q. Han ,&nbsp;D.Y. Zhang","doi":"10.1016/j.nrleng.2024.07.001","DOIUrl":"10.1016/j.nrleng.2024.07.001","url":null,"abstract":"<div><h3>Background</h3><p>Hemifacial spasm (HFS) is a debilitating disease characterized by involuntary tonic and clonic contractions of muscles innervated by the facial nerve. Botulinum toxin A (BTX-A) is the first-line option and the most effective medical treatment for HFS. The objective of this study was to evaluate the effect of BTX-A therapy on the physical and mental health of HFS patients.</p></div><div><h3>Methods</h3><p>Participants included 65 HFS patients and 65 matched healthy controls in the study. Cornell Medical Index (CMI) self-assessment questionnaire was used to detect the psychological health of all participants. Local injection of BTX-A was applied, and the Cohen hierarchical criteria were employed to stratify the degree of spasticity, further evaluating the efficacy of BTX-A before and two months after treatment in HFS patients. The HFS patients at two months post-treatment were re-evaluated by CMI self-assessment questionnaire, and the evaluated factors of these patients were compared with those of patients before treatment.</p></div><div><h3>Results</h3><p>The scores of somatization, depression, anxiety, inadaptation, sensitivity, anger, tension, M-R, and total scores in the HFS group were significantly higher than those in the control group (all <em>P</em> <!-->&lt;<!--> <!-->0.05). Two months post-treatment, among 65 HFS patients who received with BTX-A treatment, 42 (64.6%) were completely relieved, 16 (24.6%) were significantly relieved, 7 (10.8%) were partially relieved, and 0 (0%) cases were invalid, and the total effective rate was 89.2%. Two months after BTX-A treatment, the scores of somatization, tension, anxiety, depression, sensitivity, M-R and total scores of patients with HFS were lower than those before treatment (all <em>P</em> <!-->&lt;<!--> <!-->0.05).</p></div><div><h3>Conclusions</h3><p>Patients with HFS are often accompanied by somatization, anger, inadaptation, sensitivity, anxiety, depression, and tension. BTX-A can not only alleviate the symptoms of HFS, but also improve the somatization, tension, anxiety, depression, and sensitivity.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 7","pages":"Pages 540-548"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000646/pdfft?md5=0d13553a982be0b013d25e78ac129a2a&pid=1-s2.0-S2173580824000646-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the diagnostic utility of the electroencephalogram in pediatric emergencies.","authors":"M J Abenza Abildúa, T Olmedo Menchen, A Pérez Villena, S Ruhland Paulete, F José Navacerrad, Barrero, J de Ojeda Ruíz de Luna, C Algarra Lucas, G Cordero Martín, S Martínez Ubierna, C Jimeno Montero, I J Navarro López, E Suárez Gisbert, Á Gómez de la Riva, C Pérez López, M L Herreros Fernández","doi":"10.1016/j.nrleng.2024.08.001","DOIUrl":"10.1016/j.nrleng.2024.08.001","url":null,"abstract":"<p><strong>Introduction: </strong>We analyze the diagnostic utility of urgent EEG (electroencephalogram) performed in children under 16 years of age in our center.</p><p><strong>Material and methods: </strong>Descriptive, retrospective, observational study of consecutive patients from 0 to 16 years of age, who underwent an urgent EEG for any reason, from January to December 2022.</p><p><strong>Results: </strong>Of the 388 patients, 70 were children: 37 (52.85%) women, and 33 (47.14%) men. Average age: 6.27 ± 4.809. Of the 70 patients, 6 (8.57%) had previous epilepsy. Reasons for consultation: 17 febrile seizures, 10 first focal seizures, 10 first TCG seizures, 6 paroxysmal episodes, 6 absences, 3 myoclonus of extremities, 3 syncope, 2 SE, 2 visual alterations, 2 low level of consciousness, 2 cyanosis, 2 suspected meningitis or encephalitis, 1 choking, 1 atypical headache, 1 chorea, 1 presyncope, 1 language delay. Of the 70 patients, 47 had a normal EEG (67.14%). Of the 47 patients with a normal EEG, 10 were diagnosed with epilepsy, and 3 of them began receiving antiepileptic treatment upon discharge. None of the patients with suspected syncope or paroxysmal disorder (17 patients, 24.28%) had EEG abnormalities. Of the 17 patients with atypical febrile seizures, 3 had EEG abnormalities.</p><p><strong>Conclusions: </strong>A third of the EEG records performed in the Emergency Department showed alterations, probably due to the time taken. Almost half of the patients with suspected epilepsy or EE showed EEG abnormalities, which confirmed the diagnosis in these cases and encouraged the clinician to start drug treatment. No case with a high suspicion of epilepsy was dismissed due to the normality of the EEG recording in our series. No patient diagnosed with syncope or paroxysmal disorder had EEG abnormalities. Nearly a quarter of patients with atypical febrile seizures showed EEG abnormalities. We barely register cases of status epilepticus, probably due to the degree of complexity of our center.</p>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased plasma levels of N-terminal pro-B-type natriuretic peptide as biomarker for the diagnosis of cardioembolic ischaemic stroke","authors":"J.A. García-Carmona ,&nbsp;E. Conesa-García ,&nbsp;D. Vidal-Mena ,&nbsp;M. González-Morales ,&nbsp;V. Ramos-Arenas ,&nbsp;C. Sánchez-Vizcaíno-Buendía ,&nbsp;J.J. Soria-Torrecillas ,&nbsp;J.A. Pérez-Vicente ,&nbsp;L. García-de-Guadiana-Romualdo","doi":"10.1016/j.nrleng.2021.09.016","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.09.016","url":null,"abstract":"<div><h3>Background</h3><p>Despite comprehensive study, the aetiology of stroke is not identified in 35% of cases.</p></div><div><h3>Aims</h3><p>We conducted a study to assess the diagnostic capacity of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the identification of ischaemic stroke of cardioembolic origin. The secondary purpose of the study was to evaluate the prognostic value of NT-proBNP for predicting 90-day all-cause mortality.</p></div><div><h3>Methods</h3><p>We designed a prospective observational study including patients hospitalised due to stroke between March 2019 and March 2020. Blood samples were collected on admission to the emergency department and serum NT-proBNP levels were determined. Statistical analysis was performed using a bivariate logistic regression model and receiver operating characteristic (ROC) and Kaplan–Meier curves. Statistical significance was established at <em>p</em> <!-->&lt;<!--> <!-->.05.</p></div><div><h3>Results</h3><p>The study included 207 patients with first ischaemic stroke. Plasma NT-proBNP levels were significantly higher (<em>p</em> <!-->&lt;<!--> <!-->.001) in the cardioembolic stroke group (2069<!--> <!-->pg/mL<!--> <!-->±<!--> <!-->488.5). ROC curves showed that NT-proBNP<!--> <!-->&gt;<!--> <!-->499<!--> <!-->pg/mL was the optimum value for diagnosing cardioembolic ischaemic stroke (sensitivity, 82%; specificity, 80%). Moreover, plasma NT-proBNP levels<!--> <!-->&gt;<!--> <!-->499<!--> <!-->pg/mL were independently associated with cardioembolic stroke (OR: 9.881; <em>p</em> <!-->=<!--> <!-->.001). Finally, NT-proBNP<!--> <!-->&gt;<!--> <!-->1500<!--> <!-->pg/mL was useful for predicting 90-day mortality (sensitivity, 70%; specificity, 93%).</p></div><div><h3>Conclusions</h3><p>NT-proBNP was independently associated with cardioembolic stroke and should be quantified in blood tests within 24<!--> <!-->h of stroke onset. High plasma levels (&gt;499<!--> <!-->pg/mL) may indicate an underlying cardioembolic cause, which should be further studied, while NT-proBNP &gt;1500<!--> <!-->pg/mL was associated with increased 90-day mortality.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 6","pages":"Pages 496-504"},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000555/pdfft?md5=b9e6b899acf116ede9a390a6a10471f0&pid=1-s2.0-S2173580824000555-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141424122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary outcomes of endovascular treatment of moyamoya disease","authors":"Xin-Yu Li ,&nbsp;Yang-Yang Tian ,&nbsp;Cong-Hui Li,&nbsp;Ji-Wei Wang,&nbsp;Hui Li,&nbsp;Jian-Feng Liu,&nbsp;Bu-Lang Gao","doi":"10.1016/j.nrleng.2021.10.011","DOIUrl":"https://doi.org/10.1016/j.nrleng.2021.10.011","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to investigate the effectiveness and safety of endovascular revascularisation of intracranial artery occlusion and stenosis in moyamoya disease using stent angioplasty.</p></div><div><h3>Materials and methods</h3><p>We recruited 12 patients (8 women and 4 men) with occlusion and stenosis of intracranial arteries in the context of moyamoya disease who underwent endovascular stent angioplasty. Clinical data, baseline conditions, lesion location, treatment outcomes, periprocedural complications, and follow-up outcomes were analysed.</p></div><div><h3>Results</h3><p>The occlusion was located at the M1 segment of the middle cerebral artery in 8 patients, at both the M1 and A2 segments in one patient, and at the C7 segment of the internal carotid artery in 3. Thirteen stents were deployed at the occlusion site, including the low-profile visualized intraluminal support (LVIS) device in 8 patients, an LVIS device and a Solitaire AB stent in one, and a Leo stent in 3, with a success rate of 100% and no intraprocedural complications. Plain CT imaging after stenting revealed leakage of contrast agent, which disappeared on the second day, resulting in no clinical symptoms or neurological sequelae. Follow-up angiography studies were performed in all patients for 6–12 months (mean, 8.8). Slight asymptomatic in-stent stenosis was observed in 2 patients (16.7%), and no neurological deficits were observed in the other patients. All preoperative ischaemic symptoms completely disappeared at follow-up.</p></div><div><h3>Conclusion</h3><p>Stent angioplasty is a safe and effective treatment for occlusion and stenosis of intracranial arteries in moyamoya disease.</p></div>","PeriodicalId":94155,"journal":{"name":"Neurologia","volume":"39 6","pages":"Pages 449-456"},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173580824000543/pdfft?md5=5c8241e362f291f236369466a71768b7&pid=1-s2.0-S2173580824000543-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141424193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}